PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trial
— PanC-YOUNGOfficial title:
Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
NCT number | NCT05845801 |
Other study ID # | 3968 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | December 7, 2022 |
Est. completion date | September 30, 2052 |
The objective of the present registry is the creation of a prospective registry collecting clinico-pathological and genomic data, along with survival outcomes, of individuals diagnosed with PDAC at or before the age of 55 years old. This registry is intended with the aim of using collected data for future clinical trials, both prospective and retrospective.
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | September 30, 2052 |
Est. primary completion date | September 30, 2052 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Age =55 years old at the time of diagnosis of pancreatic cancer - Age = 18 years - Written informed consent obtained. Exclusion Criteria: - Any pancreatic neoplasm other than pancreatic cancer (e.g. cholangiocarcinoma, ampullary cancer,duodenal cancer, non-invasive mucinous cystic neoplasm, pancreatic intra-epithelial neoplasia 1 and 2, non-invasive intraductal papillary mucinous neoplasm, serous cystic neoplasm, pseudo papillary solid tumor, neuroendocrine tumor) - Absence of informed consent. - Age < 18 years or > 55 years old at the time of diagnosis of pancreatic cancer |
Country | Name | City | State |
---|---|---|---|
Italy | AOUI Verona | Verona |
Lead Sponsor | Collaborator |
---|---|
Azienda Ospedaliera Universitaria Integrata Verona |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Register of young PDAC patients | Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old. | 30 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT06122896 -
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
|
Early Phase 1 | |
Recruiting |
NCT05262855 -
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
|
Phase 2 | |
Recruiting |
NCT04700488 -
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
|
N/A | |
Not yet recruiting |
NCT05947825 -
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
|
Phase 2 | |
Recruiting |
NCT06151223 -
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
|
||
Recruiting |
NCT05853198 -
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
|
N/A | |
Recruiting |
NCT05669287 -
Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics
|
N/A | |
Recruiting |
NCT05727020 -
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
|
||
Recruiting |
NCT05218889 -
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05132244 -
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
|
N/A | |
Recruiting |
NCT04365049 -
Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma
|